All newsletters published in 2024
Newsletter 14 December 2024: “Alpha1 impact on serum iron status & a bit of looking back over 2024”
Newsletter 7 December 2024: “Alpha1 DNA testing by iGene”
Newsletter 30 November 2024: “Reduced bile acid secretion effects on the biliary tract”
Newsletter 23 November 2024: “Relationship between cholesterol levels and Alpha1”
Newsletter 16 November 2024: “Alpha-1 antitrypsin deficiency impact on our immune system”
Newsletter 9 November 2024: “Alpha1 MZ and type 2 diabetes”
Newsletter 2 November 2024: “Alpha1 MZ liver and our Western diet”
Newsletter 26 October 2024: “New board member; Wavelife Sciences tested RNA-editing on two humans”
Newsletter 19 October 2024: “Morbidities Summary Alpha1 SZ”
Newsletter 5 October 2024: “Alpha1 Netherlands, incl. the less known morbidities of Alpha1”
Newsletter 28 September 2024: “Air pollution impact on Alpha1 MZ & SZ patients (9/11 New York)”
Newsletter 21 September 2024: “Alpha-1 antitrypsin impact on coronavirus”
Newsletter 14 September 2024: “Skin, Eczema, Panniculitis”
Newsletter 7 September 2024: “MZ fatty liver explained”
Newsletter 31 August 2024: “Pain Medication, NSAID impact on Alpha1 MZ liver”
Newsletter 24 August 2024: “Mereo BioPharma Medication Alvelestat, inhibiting neutrophil elastase”
Newsletter 17 August 2024: “Organization Update”
Newsletter 10 August 2024: “Vit B12 Antibody & Intellia Therapeutics”
Newsletter 3 Augustus 2024: “The importance of Vitamin D for MZ’s”
Newsletter 27 July 2024: “Summary of the Alpha1 MZ disease burden”
Newsletter 20 July 2024: “Path to recognition of MZ’s”
Newsletter 13 July 2024: “Organization and research update & therapeutics”
Newsletter 6 July 2024: “Beam Therapeutics, Autism, update on intermittent pain in the liver area”
Newsletter 29 June 2024: “Intermittent pain in liver area”
Newsletter 22 June 2024: “Alpha-1 in autoimmune diseases, roles and therapeutic prospects”
Newsletter 15 June 2024: “DNA Editing therapeutics”
Newsletter 8 June 2024: “RNA Editing therapeutics”
Newsletter 1 June 2024: “RNAi therapeutics”
Newsletter 25 May 2024: “Bile acid, intestine microbiome, balsamic vinegar”
Newsletter 18 May 2024: “Genetic variation in autophagy function determines susceptibility to liver disease”
Newsletter 11 May 2024: “Connective tissue & blood vessels / aneurysm
Newsletter 4 May 2024: “Organization update; nutrition and food”
Newsletter 27 April 2024: “Chemotherapy and summary of past subjects”
Newsletter 20 April 2024: “Fatty liver”
Newsletter 13 April 2024: “Pregnancy, Cholestasis & Preeclampsia”
Newsletter 6 April 2024: “Alpha1 Antitrypsin reaction on inflammation incl Alpha1 MZ background inflammation”
Newsletter 30 March 2024: “Research update and cholestasis during pregnancy”
Newsletter 23 March 2024: “Biobank data and Serpina1 mutation variations”
Newsletter 16 March 2024: “Research progress and liver damage difference between MZ and ZZ”
Newsletter 9 March 2024: “Gut microbiota dysbiosis and MZ population worldwide”
